Find a Physician | How to Contribute | About Us | Clinical Trials
 
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Leukemia: Myeloid leukemia

A Phase 2/3 Multicenter, Open-label, 3-arm, 2-stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy

The purpose of the study is to see if a medicine called ASP2215 given alone or in combination with azacitidine is both effective and safe as a treatment for AML patients with mutations in the FLT3 gene when compared to being treated with azacitidine alone.

Status: Accepting New Patients
Principal Investigator: Shira Dinner

A Phase 1, Open-Label, Dose-Finding Study Of Cc-90009, A Novel Cereblon E3 Ligase Modulating Drug, In Subjects With Relapsed Or Refractory Acute Myeloid Leukemia

CC-90009 is a new investigational product (IP) that has a strong biological rationale for the treatment of subjects with AML. This Phase I study is designed to determine the safety and tolerability of CC-90009 as well as evaluating the biologic and clinical activity in subjects with relapsed or refractory AML.

Status: Accepting New Patients
Principal Investigator: Jessica Altman

A Phase 3, MultiCenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation

To determine if an investigational agent known as AG-221 is safe and effective in treating Late Stage Acute Myeloid Leukemia, compared with those commonly used treatment options (also called conventional care regimens).

Status: Accepting New Patients
Principal Investigator: Olga Frankfurt

A Phase I, Open, Cohort Dose Escalation Trial with BI 836858 in Patients with Refractory or Relapsed Acute Myeloid Leukemia

The purpose of this research study is three-fold: to identify the maximum tolerated dose, that is, the highest dose of the study drug that does not cause unacceptable side effects; to obtain information on the safety and effectiveness in people given the study drug alone; and to measure and evaluate the behavior of the study drug in the blood.

Status: Accepting New Patients
Principal Investigator: Jessica Altman

An Open-Label, Phase 1b/2 Study Investigating Recommended Phase 2 Dose, Safety, Tolerability, and Preliminary Efficacy of TAK-659 in Adult Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

This study is divided into 2 parts. The main purpose of the first part of this study (phase 1b) is to evaluate the side effects and risks of an investigational drug, TAK-659, to identify the highest dose that can be tolerated safely, and to decide upon the recommended dose for the second part of the study. The second part of this study (phase 2) will evaluate how well AML responds to the investigational drug.

Status: Accepting New Patients
Principal Investigator: Olga Frankfurt

A Randomized Open-Label Pilot Trial to Evaluate the Safety and Efficacy of Repetitive Transcranial Magnetic Stimulation in Cancer Patients with Depression and Anxiety

The purpose of this study is to test the safety and tolerability of left- and right-sided rTMS as a treatment for depression in the cancer population.

Status: Accepting New Patients
Principal Investigator: Mehmet Dokucu

Extended Duration Varenicline for Smoking among Cancer Patients: A Clinical Trial

The main purpose of this research study is to compare 12 versus 24 weeks of varenicline treatment, also known as Chantix®, for smoking cessation.

Status: Accepting New Patients
Principal Investigator: Brian Hitsman

last updated: Sat - August 19, 2017 - 09:25 AM

Fetching Clinical Trial!

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.